Dana dhuwit perusahaan: acelyrin.com (SLRN)

Tandha merek acelyrin.com (SLRN)

Risks associated with the dependence on retaining rare scientific personnel through stock options impact the cash balance, where the parameter has settled at 0.41. The sale of izakibept through insurance systems for the treatment of psoriasis will ensure stability for Acelyrin, Inc. (SLRN). Growth prospects are based on scaling research into molecules targeting severe skin and eye pathologies.

SLRN - Aset likuid perusahaan ACELYRIN, Inc. ing rentang 21.02.2024 - 31.05.2025

Rincian metrik keuangan lan pasar ACELYRIN (SLRN)

- rega saiki lan proyeksi nilai saham:
- indikator kapitalisasi bursa perusahaan:
Analisis dhasar perusahaan:SLRN ACELYRIN
Sampel barang acelyrin.com

Liquidity serves as the foundation of operational resilience for Acelyrin, Inc. (SLRN). This indicator measures the total volume of cash and cash equivalents available to cover short-term liabilities. By analyzing cash balances in accounts and on hand, investors assess the company's ability to fund R&D without external borrowing. The current capital reserve ensures the execution of key Phase 2/3 trials for anti-inflammatory molecules. This liquidity factor is already fully priced into the current market value of the shares.

Karo sapa Acelyrin, Inc. saingan

Dana dhuwit perusahaan Haleon (HLN)|Volume dana dhuwit perusahaan Kenvue Inc. (KVUE)|Volume dana dhuwit perusahaan VRNA (veronapharma.com)|Sisa dhuwit perusahaan MENS|LGND: Dhuwit awis perusahaan|Sisa dhuwit perusahaan AMRX (Amneal Corp)|PRGO (Perrigo Company plc) - Dhuwit awis perusahaan|Alvotech - Sisa dhuwit perusahaan|Dhuwit awis perusahaan LQDA|Galapagos Genomics (GLPG) - Aset likuid perusahaan|Volume dana dhuwit perusahaan ANIP|Dhuwit awis perusahaan Afrezza MNKD|Dana dhuwit perusahaan Amphastar AMPH|Aset likuid perusahaan Pacira BioSciences (PCRX)|ARS Corp - Volume dana dhuwit perusahaan|TBPH: Dana dhuwit perusahaan|AQST: Volume dana dhuwit perusahaan|SCPH - Aset likuid perusahaan|TECX (Tectonic) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Tonix Pharmaceuticals Holding Corp. TNXP|Dana dhuwit perusahaan SXT Pharmaceuticals (SXTC)|Volume dana dhuwit perusahaan Eupraxia Pharmaceuticals Inc. (EPRX)|Dana dhuwit perusahaan BioHarvest Sciences BHST|EXOZ (Invizyne) - Total volume dana dhuwit perusahaan|ORMP: Dhuwit awis perusahaan|ENTX (Entera Bio Ltd) - Dhuwit awis lan setara dhuwit awis perusahaan|HYFT: Volume dana dhuwit perusahaan|Dhuwit awis perusahaan ABVC BioPharma Inc.|CPIX (cumberlandpharma.com) - Volume dana dhuwit perusahaan|Dana dhuwit perusahaan QNTM|Volume dana dhuwit perusahaan FGEN|Dhuwit awis perusahaan Telomir Pharmaceuticals TELO|Volume dana dhuwit perusahaan RANI (ranitherapeutics.com)|SNYR (Synergy CHC Corporation) - Total volume dana dhuwit perusahaan|RLYB - Dana dhuwit perusahaan|LEXX (Lexaria Bioscience Corp.) - Dhuwit awis lan setara dhuwit awis perusahaan|pulmatrix.com (PULM) - Dana dhuwit perusahaan|PTHL (Pheton) - Dana dhuwit perusahaan|Dana dhuwit perusahaan Aptorum|Cadangan dhuwit perusahaan Lyra Therapeutics Inc. LYRA|Volume dana dhuwit perusahaan IBO|TNFA (TNF Pharmaceuticals, Inc.) - Sisa dhuwit perusahaan|Dana dhuwit perusahaan cbdMD, Inc. YCBD|Sisa dhuwit perusahaan PRFX|Altamira Therapeutics Ltd. - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Lipella Pharmaceuticals Inc|OPTN: Volume dana dhuwit perusahaan|Pieris - Sisa dhuwit perusahaan|Dhuwit awis perusahaan PROC|Volume dana dhuwit perusahaan petrospharma.com|Dana dhuwit perusahaan Qilian International Corp (QLI)|TFFP (TFF Pharmaceuticals Inc.) - Sisa dhuwit perusahaan